Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant

被引：0
|
作者：
Vo, A. [1 ]
Choi, J. [1 ]
Kim, I. [1 ]
Huang, E. [1 ]
Louie, S. [1 ]
Kang, A. [1 ]
Williamson, S. [1 ]
Myers, K. [1 ]
Peng, A. [1 ]
Najjar, R. [1 ]
Jordan, S. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Kidney Transplant, Los Angeles, CA 90048 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2017年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
108
引用
收藏
页码：244 / 245
页数：2
相关论文
共 50 条
  • [21] EVALUATING THE EFFECT OF ANTI-TNF, ANTI-IL6R AND ANTI-CTLA4 ON ACPA ISOTYPES IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Hernandez-Florez, D.
    del Rio, T.
    Nieto, J.
    Ovalles, J.
    Martinez, J.
    Serrano, B.
    Mata, C.
    Gonzalez, C.
    Monteagudo, I.
    Lopez-Longo, J.
    Naredo, E.
    Valor, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 901 - 902
  • [22] Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up.
    Vo, A.
    Tang, J.
    Ammerman, N.
    Huang, E.
    Zhang, X.
    Haas, M.
    Peng, A.
    Najjar, R.
    Williamson, S.
    Meyers, C.
    Sethi, S.
    Lim, K.
    Gillespie, M.
    Badash, N.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 508 - 508
  • [23] Anti-HLA antibody-induced rejection in ABO-incompatible kidney transplant patients.
    Kong, Jin
    Whang, Eun J.
    Jeong, Joon H.
    Choi, Won Y.
    Son, Sung H.
    Kwon, Hyuk Y.
    TRANSPLANTATION, 2016, 100 (07) : S579 - S579
  • [24] Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG plus Rituximab
    Vo, A.
    Choi, J.
    Kim, I.
    Kahwaji, J.
    Peng, A.
    Villicana, R.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [25] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    TRANSPLANTATION, 2014, 98 : 115 - 115
  • [26] LINEAR IGA BULLOUS DERMATOSIS IN A KIDNEY TRANSPLANT RECIPIENT WITH ELEVATED BULLOUS INTERLEUKIN-6 LEVELS: RESPONSIVE TO TREATMENT WITH TOCILIZUMAB (ANTI-IL-6R)
    Jordan, S. C.
    Balzer, B.
    Nast, C.
    Atiznea, J.
    Lim, K.
    Kumar, S.
    Nissen, N.
    Shin, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (01) : NP495 - NP495
  • [27] Regulatory T Cell (Treg) and Cytokine Levels Post-Tocilizumab (TCZ, Anti-IL-6R) Desensitization (DES) in HLA-Sensitized Patients (HS Pts).
    Shin, B.
    Ge, S.
    Karasyov, A.
    Watanabe, J.
    Choi, J.
    Lovato, D.
    Vo, A.
    Jordan, S.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 115 - 115
  • [28] Combined Anti-IL6R and CTLA4Ig Therapy Attenuates Recall Alloantibody Responses in a Mouse Model of HLA Sensitization
    Chai, N. -N.
    Wu, G.
    Kim, I.
    Klein, A.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [29] Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR).
    Shin, B.
    Ge, S.
    Petrosyan, A.
    Ammerman, N. F.
    Vo, A. A.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
  • [30] SYSTEMIC LEVELS OF TYPE VI COLLAGEN METABOLITES ARE ELEVATED IN RA PATIENTS AND MODULATED BY TREATMENT WITH ANTI-IL6R THERAPY
    Thudium, C. S.
    Gudmann, N. S.
    Karsdal, M.
    Bay-Jensen, A. -C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 846 - 846
12345